Amgen Sues Pfizer, Hospira As Neulasta Patent Feud Widens

Law360 (February 12, 2020, 6:25 PM EST) -- Pfizer Inc. and Hospira Inc. infringed an Amgen Inc. patent when seeking to get its biosimilar of Amgen's blockbuster anti-infection medicine Neulasta on the market before the patent expired, the biologic maker told a Delaware federal court.

Amgen said in its lawsuit filed Tuesday that Pfizer and its subsidiary Hospira infringed U.S. Patent No. 8,273,707 and developed its own biosimilar "predicated on plaintiffs' trailblazing efforts." The suit comes after the companies engaged in the so-called patent dance provisions of the Biologics Price Competition and Innovation Act, in which the biosimilar maker shares information about its products to identify potentially infringed patents....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!